Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients

Abstract

Introduction

Adherence to imatinib in chronic myeloid leukemia (CML) patients is estimated to be as low as 70% despite its clinical benefit, and our understanding of the impact of nonadherence in this population is limited. This study presents a novel application of the Alternating Conditional Estimation (ACE) algorithm in newly diagnosed CML patients to map the full dose–response curve (DRC) and determine how the strength of this curve varies over time.

Methods

We applied the ACE algorithm alongside a backward elimination procedure to detect the presence of time dependence and nonlinearity in the relationship between imatinib adherence and time-to-remission. An extended Cox model allowing for the flexible modeling of identified effects via unpenalized B-splines was subsequently fit and assessed.

Results

The substantial improvement in model fit associated with the extended Cox approach suggests that traditional Cox proportional hazards model assumptions do not hold in this setting. Results indicate that the DRC for imatinib is non-linearly increasing, with an attenuated effect above a 74% adherence rate. The strength of this effect on remission varied over time and was strongest in the initial months of treatment, reaching a peak around 90 days post-initiation (log hazard ratio: 2.12, 95% confidence interval: 1.47 to 2.66).

Conclusion

Most patients that achieved remission did so by 4 months (120 days) with consistently high adherence, suggesting that this could be a critical time and duration for realizing treatment benefit and patient monitoring. Findings regarding the relationship between adherence and remission can additionally help guide the design of future studies.

Keywords

Adherence chronic myeloid leukemia imatinib survival analysis longitudinal dose response

Get full access to this article

View all access options for this article.

References

Deininger

Shah

Altman

, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020; 18: 1385–1415.

Bower

Björkholm

Dickman

, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. JCO 2016; 34: 2851–2857.

Jabbour

Kantarjian

. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 2020; 95: 691–709.

Marin

Bazeos

Mahon

, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381–2388.

Noens

van Lierde

De Bock

, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113: 5401–5411.

Iqbal

. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract 2014; 2014: 357027.

Gambacorti-Passerini

Chen

Davis

, et al. Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data. Eur J Haematol 2021; 106: 82–89.

Noens

Hensen

Kucmin-Bemelmans

, et al. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 2014; 99: 437–447.

Ibrahim

Eliasson

Apperley

, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733–3736.

10.

Ganesan

Sagar

Dubashi

, et al. Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011; 86: 471–474.

11.

Clark

Marcum

Radich

, et al. Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia. J Oncol Pharm Pract 2021; 27: 1842–1852.

12.

Yeager

Waldrop-Valverde

Paul

, et al. Adherence trajectories in oral therapy for chronic myeloid leukemia: overview of a research protocol. Res Nurs Health 2020; 43: 443–452.

13.

Johnson

Beaulieu

, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010; 26: 61–69.

14.

Yood

Oliveria

Cziraky

, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012; 28: 213–219.

15.

Ward

Fang

Richards

, et al. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Curr Med Res Opin 2015; 31: 289–297.

16.

Altman

Royston

. The cost of dichotomising continuous variables. Br Med J 2006; 332: 1080.

17.

Altman

Lausen

Sauerbrei

, et al. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. JNCI Journal of the National Cancer Institute 1994; 86: 829–835.

18.

Tueller

Deboeck

Van Dorn

. Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data. J Behav Med 2016; 39: 969–980.

19.

Kalbfleisch

Prentice

RL.

The statistical analysis of failure time data. 2. Aufl. Hoboken: Wiley-Interscience; 2011. (Wiley series in probability and statistics).

20.

Breslow

. The proportional hazards model: applications in epidemiology. Communications in Statistics–Theory and Methods 1978; 7: 315–332.

21.

Sylvestre

Abrahamowicz

. Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. Stat Med 2009; 28: 3437–3453.

22.

Sauerbrei

Meier-Hirmer

Benner

, et al. Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data Anal 2006; 50: 3464–3485.

23.

Royston

. Flexible parametric alternatives to the Cox model, and more. Stata J 2001; 1: 1–28.

24.

Abrahamowicz

MacKenzie

. Joint estimation of time-dependent and non-linear effects of continuous covariates on survival. Stat Med 2007; 26: 392–408.

25.

Wynant

Abrahamowicz

. Validation of the alternating conditional estimation algorithm for estimation of flexible extensions of Cox’s proportional hazards model with nonlinear constraints on the parameters. Biom J 2016; 58: 1445–1464.

26.

Wang

Beauchamp

Abrahamowicz

. Nonlinear and time-dependent effects of sparsely measured continuous time-varying covariates in time-to-event analysis. Biom J 2020; 62: 492–515.

27.

Healthcare [Internet]. TriNetX. [cited 2022 Oct 10]. https://trinetx.com/healthcare-organizations/ (2022, accessed 5 May 2022).

28.

Hochhaus

Baccarani

Silver

, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34: 966–984.

29.

Trivedi

Landsman-Blumberg

Darkow

, et al. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. JMCP 2014; 20: 1006–1015.

30.

Abrahamowicz

Beauchamp

Sylvestre

. Comparison of alternative models for linking drug exposure with adverse effects. Stat Med 2012; 31: 1014–1030.

31.

Loucks

Zuckerman

Berni

, et al. Proportion of days covered as a measure of medication adherence. Am J Health Syst Pharm 2022; 79: 492–496.

32.

Horsky

Drucker

Ramelson

. Accuracy and completeness of clinical coding using ICD-10 for ambulatory visits. AMIA Annu Symp Proc. 2018;2017: 912–920.

33.

Quan

Couris

, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173: 676–682.

34.

Charlson

Pompei

Ales

, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.

35.

Darkow

Henk

Thomas

, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25: 481–496.

36.

Wynant

Abrahamowicz

. Impact of the model-building strategy on inference about nonlinear and time-dependent covariate effects in survival analysis. Stat Med 2014; 33: 3318–3337.

37.

Sauerbrei

Royston

Binder

. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007; 26: 5512–5528.

38.

Abrahamowicz

Mackenzie

Esdaile

. Time-Dependent Hazard ratio: modeling and hypothesis testing with application in lupus nephritis. J Am Stat Assoc 1996; 91: 1432–1439.

39.

Abrahamowicz

Ramsay

. Multicategorical spline model for item response theory. Psychometrika 1992; 57: 5–27.

40.

Austin

Fang

Lee

. Using fractional polynomials and restricted cubic splines to model non-proportional hazards or time-varying covariate effects in the Cox regression model. Stat Med 2022; 41: 612–624.

41.

de Almeida

Fogliatto

Couto

. Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Rev Bras Hematol Hemoter 2014; 36: 54–59.

42.

O’Quigley

Pessione

. The problem of a covariate-time qualitative interaction in a survival study. Biometrics 1991; 47: 101–115.

43.

Robins

. Association, causation, and marginal structural models. Synthese 1999; 121: 151–79.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB